BioSpace News Archive

NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced it will host the third of four virtual R&D events on Tuesday, May 31, 2022, from 12:00 pm – 1:15 pm ET.

An improvement in the healthcare sector in developing nations and advancement in technology, along with support from the government, has driven the demand for the market.

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) has been informed by medac, a strategic partner of Medexus, that medac received acknowledgement of receipt from the U.S. Food and Drug Administration (FDA) of the New Drug Application resubmission for Treosulfan (NDA) submitted on April 21, 2022, together with a request to submit information in order to complete medac’s NDA resubmission and initiate FDA review.

Increasing incidence of musculoskeletal disorders, rising geriatric population across the globe, and growing awareness about advanced treatments...

Rising prevalence of chronic and acute diseases and rapidly growing geriatric population are among the major factors driving the global market revenue growth

Rising prevalence of various life-threatening diseases across the globe, rapid advancements in nanotechnology, and increasing demand for nanotechnology based services...

Rising prevalence of sports injuries, chronic conditions, and spinal injuries worldwide, increasing overall healthcare expenditure, and technological advancements in electrotherapy systems are some key factors expected to drive global market growth

Reports and Data has recently added a research report on Temporary Pacemaker Market By Product Type (Single Chamber Pacemaker, Dual Chamber Pacemaker, Triple Chamber Pacemaker), By End-use (Hospitals, Specialty Clinics, Others), and By Region Forecast to 2028. The report offers detailed overview of the market with recent market dynamics and industrial status.

Genexine a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, announced the appointment of Neil Warma as its President and Chief Executive Officer.

Specialty cancer diagnostics company, Precipio, Inc. (NASDAQ: PRPO), today announced that it has received CE-IVD approval for sale of its HemeScreen® reagents in the European Union.